Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer
Open Access
- 11 July 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 942380
Abstract
Background: For gynecological cancer patients, the beneficial effect of metformin use remains controversial due to inconsistent results of published articles. By conducting a meta-analysis, we aimed to evaluate the effect of metformin in reducing the risk and improving the survival of gynecological cancer among women with diabetes mellitus (DM).Methods: Articles exploring association between metformin use and the risk, as well as prognosis of gynecologic cancer in DM, were searched in the databases: PubMed, Web of Science, SCOPUS, EMBASE, EBSCO, and PROQUEST. Articles were published before May 2022. All the studies were conducted using STATA 12.0 software.Results: The meta-analysis showed no significant association between metformin use and risk of gynecologic cancer in DM with a random effects model [odds ratio (ORs)/relative risk (RR) = 0.91, 95% confidence intervals (CI) 0.77 to 1.08, I2 = 84.2%, p < 0.001]. Metformin use was associated with reduced overall survival (OS) and progression-free survival (PFS) of gynecologic cancer in DM with random effects models [OS: hazard ratio (HR) = 0.60, 95% CI 0.49–0.74, I2 = 55.2%, p = 0.002; PFS: HR = 0.55, 95% CI 0.33–0.91, I2 = 69.1%, p = 0.006], whereas no significant association was showed between metformin use and recurrence-free survival (RFS), as well as cancer-specific survival (CSS) of gynecologic cancer in DM with random effects models (RFS: HR = 0.60, 95% CI 0.30–1.18, I2 = 73.7%, p = 0.010; CSS: HR = 0.78, 95% CI 0.43–1.41, I2 = 72.4%, p = 0.013).Conclusions: In conclusion, this meta-analysis indicated that metformin may be a useful adjuvant agent for gynecological cancer with DM, especially for patients with ovarian cancer and endometrial cancer.Keywords
This publication has 64 references indexed in Scilit:
- Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse modelsAmerican Journal of Obstetrics and Gynecology, 2015
- Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2014
- Association between diabetes, diabetes treatment and risk of developing endometrial cancerBritish Journal of Cancer, 2014
- Metformin is associated with improved survival in endometrial cancerGynecologic Oncology, 2014
- Metformin use and endometrial cancer survivalGynecologic Oncology, 2014
- Metformin and the risk of endometrial cancer: A case–control analysisGynecologic Oncology, 2013
- Metformin intake is associated with better survival in ovarian cancerCancer, 2012
- Mortality After Incident Cancer in People With and Without Type 2 DiabetesDiabetes Care, 2012
- Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and ChemosensitivityObstetrics & Gynecology, 2012
- Use of metformin and the risk of ovarian cancer: A case–control analysisGynecologic Oncology, 2011